Editorial comment: erythropoietin for treatment-related anemia in persons with hepatitis C--questions remain.
Yachimski
Patrick
P
Chung
Raymond T
RT
D000740:Anemia / Q000139:chemically induced* / Q000453:epidemiology / Q000517:prevention & control*; D000998:Antiviral Agents / Q000008:administration & dosage / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D004921:Erythropoietin / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications*; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage / Q000009:adverse effects*; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage* / Q000009:adverse effects
D000998:Antiviral Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D004921:Erythropoietin; D012254:Ribavirin